Cargando…

Characteristics of SARS-CoV-2 Delta variant-infected individuals with intermittently positive retest viral RNA after discharge

Detalles Bibliográficos
Autores principales:	Li, Lu, Tang, Jingyan, Xie, Zhiwei, Gan, Qingxin, Tang, Guofang, Hu, Zhongwei, Zeng, Huimin, Shi, Jingrong, Li, Jiaojiao, Li, Yan, Ke, Changwen, Kang, Min, Liang, Dan, Lu, Huan, Tong, Yuwei, Deng, Xilong, Liu, Jinxin, Lu, Hongzhou, Wang, Fuxiang, Hu, Fengyu, Li, Feng, Zhong, Nanshan, Tang, Xiaoping
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2022
Materias:	Special Section: SARS-CoV-2
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9616468/ https://www.ncbi.nlm.nih.gov/pubmed/36325114 http://dx.doi.org/10.1093/nsr/nwac141

Ejemplares similares

Thrombose und COVID-19
por: Tzaneva, Stanislava
Publicado: (2021)

LBA69 Impact of the COVID-19 pandemic on management of medical cancer treatments and psychological consequence for the patients
por: Joly, F., et al.
Publicado: (2020)

Clinical evaluation of SARS-CoV-2 point-of-care antibody tests
por: Robosa, Roselle S., et al.
Publicado: (2020)

Sample pooling is a viable strategy for SARS-CoV-2 detection in low-prevalence settings
por: Chong, Brian S.W., et al.
Publicado: (2020)

Virus isolation of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) for diagnostic and research purposes
por: Stelzer-Braid, Sacha, et al.
Publicado: (2020)

SARS-CoV-2 positivity in rectal swabs: implication for possible transmission
por: Novazzi, Federica, et al.
Publicado: (2020)

Clinical evaluation of four commercial immunoassays for the detection of antibodies against established SARS-CoV-2 infection
por: Chua, Kyra Y.L., et al.
Publicado: (2020)

Laboratory biosafety measures involving SARS-CoV-2 and the classification as a Risk Group 3 biological agent
por: Kaufer, Alexa M., et al.
Publicado: (2020)

Azithromycin and SARS-CoV-2 infection: Where we are now and where we are going
por: Parra-Lara, Luis Gabriel, et al.
Publicado: (2020)

LBA8 Vaccination against SARS-CoV-2 in patients receiving chemotherapy, immunotherapy, or chemo-immunotherapy for solid tumors
por: Oosting, S., et al.
Publicado: (2021)

What prompts clinicians to start antibiotic treatment in COVID-19 patients? An Italian web survey helps us to understand where the doubts lie
por: Colaneri, Marta, et al.
Publicado: (2021)

In vitro evaluation of the virucidal activity of disodium citrate perhydrate (2SCP) disinfectant against SARS-CoV-2
por: Dessilly, Géraldine, et al.
Publicado: (2022)

Back to the future (of common respiratory viruses)
por: Mattana, Giordana, et al.
Publicado: (2022)

Protective neutralizing epitopes in SARS‐CoV‐2
por: Liu, Hejun, et al.
Publicado: (2022)

Effect of farnesyltransferase inhibitors on SARS-CoV-2
por: Weber, Lea, et al.
Publicado: (2023)

Elevated plasma levels of selective cytokines in COVID-19 patients reflect viral load and lung injury
por: Liu, Yingxia, et al.
Publicado: (2020)

Plasma metabolomic and lipidomic alterations associated with COVID-19
por: Wu, Di, et al.
Publicado: (2020)

An individualized algorithm to predict mortality in COVID-19 pneumonia: a machine learning based study
por: Laino, Maria Elena, et al.
Publicado: (2022)

Ventilation support in SARS-CoV-2 pneumonia. Strategy and indications
por: Gordo, Federico, et al.
Publicado: (2022)

Respiratory consequences after COVID-19: outcome and treatment
por: Molina-Molina, María, et al.
Publicado: (2022)

Immune treatment in COVID-19
por: Menéndez, Rosario, et al.
Publicado: (2022)

Steroid therapy and antiviral treatment in SARSCoV-2 pneumonia: clinical contexts and indications
por: Torres, Antoni, et al.
Publicado: (2022)

Respiratory infections in Coronavirus disease 2019
por: del Pozo, Jose L.
Publicado: (2022)

Lineage-specific positive selection on ACE2 contributes to the genetic susceptibility of COVID-19
por: Pan, Yuwen, et al.
Publicado: (2022)

Report of the National Institutes of Health SARS-CoV-2 Antiviral Therapeutics Summit
por: Hall, Matthew D, et al.
Publicado: (2021)

Vaccination strategies against SARS-CoV-2: General impact on the development of the pandemic
por: de Miguel, Ángel Gil, et al.
Publicado: (2021)

Infection and infectivity: Utility of rapid antigen tests for the diagnosis of COVID-19
por: Barreiro, Pablo, et al.
Publicado: (2021)

Comprehensive serological strategy for the diagnosis and monitoring of SARS-CoV-2. From infection to vaccine control
por: Delgado, Rafael
Publicado: (2021)

COVID-19 and fungal infections: Etiopathogenesis and therapeutic implications
por: Chumbita, Mariana, et al.
Publicado: (2021)

Role of molecular diagnostics in the clinical management of SARS-CoV-2 infection: advantages and drawbacks
por: Martín-Higuera, Carmen, et al.
Publicado: (2021)

Approach to COVID-19 pandemic management in Madrid. Chronic of a year
por: Candel, Francisco Javier, et al.
Publicado: (2021)

Antiviral therapy and immunotherapy of COVID-19
por: Crespillo, Clara, et al.
Publicado: (2021)

Respiratory co-and superinfections in COVID-19
por: del Pozo, José L
Publicado: (2021)

COVID-19: Impact on prescribing and antimicrobial resistance
por: Ruiz-Garbajosa, Patricia, et al.
Publicado: (2021)

Ventilatory support and corticosteroid therapy in SARS-CoV-2
por: Sagasti, Fernando Martínez, et al.
Publicado: (2021)

Vulnerability to SARS-CoV-2 infection and disease: ripping the curl after the storm
por: Barreiro, Pablo, et al.
Publicado: (2022)

Management of hyperinflammation in COVID-19 patients
por: Suberviola, Borja, et al.
Publicado: (2022)

Neutralizing antibodies for SARS-CoV-2 infection
por: Berenguer, Juan
Publicado: (2022)

Antiviral drugs against SARS-CoV-2
por: Aiello, Tommaso Francesco, et al.
Publicado: (2022)

Implementation and evaluation of a novel real-time multiplex assay for SARS-CoV-2: in-field learnings from a clinical microbiology laboratory
por: Williams, Eloise, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_7qmcse28trm9t7ect2vftn9hef